Galapagos 2018. De inhoudelijke discussie. In its Q3 call, Gilead indicated contemplating to discuss with the FDA thepossibility of a rolling submission, i.e. filling MANTA later than clinical RAdata (n.b. the submission will still require ... Forumberichten 10 apr | Door: Wall Street Trader Forum: Galapagos
inhoudelijk LIGHT Analyst Price TargetsCantor Fitzgerald Price Target $150SVBLeerink 28 maart 2019 OUTPERFORMRBC 28 maart 2019 Sector PerformBerenberg 29 maart 2019 Price Target € 112Barclays Capital 29 maart 2019 P... Forumberichten 29 mrt | Door: Wall Street Trader Forum: Galapagos
Analyst reports 2019 Analyst Price TargetsCantor Fitzgerald Price Target $150SVBLeerink 28 maart 2019 OUTPERFORMRBC 28 maart 2019 Sector PerformBerenberg 29 maart 2019 Price Target € 112Barclays Capital 29 maart 2019 P... Forumberichten 29 mrt | Door: Wall Street Trader Forum: Galapagos
Galapagos december 2018 Because of all the crap on this thread are first post and hint before the FINCH-2 data came out only got picked up by Piddybull. So shout out to you.In are first post we forgot to mention Lama Dail... Forumberichten 30 nov | Door: Wall Street Trader Forum: Galapagos
Galapagos augustus 2018 We expect Gilead to present topline results of the FINCH-2 study set at the next ACR conference, 19th-24th October 2018Shout out to: Biotech Radar, pe26, Volker Schulz, BioStockAddict, NielsjeB, Vo... Forumberichten 09 aug | Door: Wall Street Trader Forum: Galapagos